Government and Global Health Initiatives Accelerate Flu Influenza Vaccine Market Growth

Flu influenza vaccine market size was $8.4 billion in 2024 and is projected to reach $16.3 billion by 2035, growing at a CAGR of 6.6% during the forecast period (2025–2035). Public health authorities globally are prioritizing large-scale vaccine procurement and development, demonstrating a proactive approach to influenza preparedness and fueling market expansion. For instance, in May 2025, the US Department of Health and Human Services and the NIH have committed $500 million to the ‘Generation Gold Standard’ universal vaccine program, aimed at influenza and coronaviruses via a beta-propiolactone-inactivated whole-virus platform. The drugs, BPL-1357 and BPL-24910, are expected to begin in human trials by 2026.

Browse the full report description of “Flu Influenza Vaccine Market Size, Share & Trends Analysis Report by Vaccine Type (Quadrivalent, and Trivalent), by Technology (Egg-Based, and Cell Culture), by Age Group (Pediatric, and Adult), and by Route of Administration (Injection, and Nasal Spray) Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/flu-influenza-vaccine-market

• In March 2025, Osivax raised $11.0 million of Series B funding to allow for further development of its candidate broad-spectrum influenza vaccine, OVX836, encompassing a Phase 2b field efficacy trial. The funding was used to advance the clinical development of the vaccine.

• In July 2024, the US Department of Health and Human Services (HHS), via the Biomedical Advanced Research and Development Authority, invested $176?million to support Moderna’s development of an mRNA vaccine targeting H5N1 avian influenza, alongside purchasing 4.8?million doses of a cell-based H5N1 vaccine for inclusion in the National Pre-Pandemic Influenza Vaccine Stockpile; Moderna has already begun early-stage trials (for H5 and H7 strains) and aims to move into Phase?3 testing in 2025—efforts to bolster pandemic preparedness remain aligned with CDC assessments that current human risk is low.

Market Coverage

• The market number available for – 2024-2035

• Base year- 2024

• Forecast period- 2025-2035

• Segment Covered- 

o By Vaccine Type

o By Technology

o By Age Group

o By Route of Administration

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape – AstraZeneca plc, CSL Seqirus Inc., GSK plc, Moderna, Inc., and Sanofi, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Flu Influenza Vaccine Market Report Segment

By Vaccine Type

• Quadrivalent 
• Trivalent

By Technology

• Egg-Based 
• Cell Culture

By Age Group

• Pediatric 
• Adult

By Route of Administration

• Injection 
• Nasal Spray

Global Flu Influenza Vaccine Market Report Segment by Region

North America

• United States

• Canada 

Europe

• UK

• Germany

• Italy

• Spain

• France

• Russia

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Australia and New Zealand

• ASEAN Economies

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/flu-influenza-vaccine-market